In the course of the study of MBP/EAE system, we have been successful in establishing a prototypic model of """"""""molecular-mimicry"""""""" or antigenic crossreactivity at the T cell clonal level. In this system, T cell lines and clones specific for Ac1-9 of myelin basic protein (MBP) recognize determinants on chimeric peptides made up of different regions of the MBP sequence, 7-11:35-47 and 7-11:35-44, which have only a 3 amino acid overlap with Ac1-9. This system offers the possibility of examining in detail T cell crossreactivity at the clonal level, and such provide new insights pertaining to recognition of antigen-MHC complexes by T cells. Important questions to be answered are (a) whether T cell crossreactivity could occur in the absence of any significant sequence homology (b) whether the mimicry peptide will bind MHC in a homologous fashion (c) and what is the relationship between crossreactivity and TcR receptor gene expression. In this study we will define the critical amino acids residues on the chimeric peptides and determine whether they are TcR contact or MHC binding residues. Additionally, we will analyze the similarity of binding of the Ac1-9 and chimeric peptides to MHC. The relationship between TcR gene usage and crossreactivity will be examined. Lastly, we will study the hindering effect of the 2 additional amino terminal residues (R-5 and P-6) in 5-11:35-44 and 5-11:35-47. Antigenic crossreactivity has been frequently evoked as a mechanism which plays both a central role in the shaping of the T cell repertoire and in initiating autoimmune diseases. Our model should provide a clear insight into the mechanism underlying T cell mimicry at the clonal level.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Brahn, E; Lehman, T J; Peacock, D J et al. (1999) Suppression of coronary vasculitis in a murine model of Kawasaki disease using an angiogenesis inhibitor. Clin Immunol 90:147-51
Oliver, S J; Cheng, T P; Banquerigo, M L et al. (1998) The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol 25:964-9
Hahn, B H (1997) The potential role of autologous stem cell transplantation in patients with systemic lupus erythematosus. J Rheumatol Suppl 48:89-93
Hahn, B H; Singh, R R; Tsao, B P et al. (1997) Peptides from Vh regions of antibodies to DNA activate T cell help to upregulate autoantibody synthesis. Lupus 6:330-2
Melo, M E; Goldschmidt, T J; Bhardwaj, V et al. (1996) Immune deviation during the induction of tolerance by way of nasal installation: nasal installation itself can induce Th-2 responses and exacerbation of disease. Ann N Y Acad Sci 778:408-11
Oliver, S J; Brahn, E (1996) Combination therapy in rheumatoid arthritis: the animal model perspective. J Rheumatol Suppl 44:56-60
Singh, R R; Hahn, B H; Sercarz, E E (1996) Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell-mediated autoimmunity. J Exp Med 183:1613-21
Singh, R R; Ebling, F M; Sercarz, E E et al. (1995) Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 96:2990-6
Zack, D J; Wong, A L; Stempniak, M et al. (1995) Two kappa immunoglobulin light chains are secreted by an anti-DNA hybridoma: implications for isotypic exclusion. Mol Immunol 32:1345-53
Zack, D J; Yamamoto, K; Wong, A L et al. (1995) DNA mimics a self-protein that may be a target for some anti-DNA antibodies in systemic lupus erythematosus. J Immunol 154:1987-94

Showing the most recent 10 out of 30 publications